+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Combination of gemcitabine and doxorubicin in sarcomatoid and/or rapidly progressive metastatic renal cell carcinoma (MRCC)



Combination of gemcitabine and doxorubicin in sarcomatoid and/or rapidly progressive metastatic renal cell carcinoma (MRCC)








Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 020742242

Download citation: RISBibTeXText


Related references

Poster Combination of gemcitabine and doxorubicin in sarcomatoid and/or rapidly progressive metastatic renal cell carcinoma (Mrcc). European Journal of Cancer Supplements 5(4): 308-309, 2007

Combination of gemcitabine and doxorubicin in rapidly progressive metastatic renal cell carcinoma and/or sarcomatoid renal cell carcinoma. Oncology 80(3-4): 214-218, 2011

Successful mammalian target of rapamycin inhibitor maintenance therapy following induction chemotherapy with gemcitabine and doxorubicin for metastatic sarcomatoid renal cell carcinoma. Oncology Letters 8(1): 464-466, 2014

Metastatic renal cell carcinoma (mRCC) patients (pts) with sarcomatoid features treated with VEGF-targeted therapy. Journal of Clinical Oncology 26(15_suppl): 5102-5102, 2016

A 51-year-old man with rapidly progressive metastatic sarcomatoid renal cell carcinoma: an apparent complete clinical response to second-line therapy with sunitinib and low-dose interferon-alpha. Clinical Advances in Hematology and Oncology 9(1): 61-64, 2011

Single agent gemcitabine (gem) in metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology 23(16_suppl): 4798-4798, 2016

Combination of sorafenib and weekly gemcitabine in patients (pts) with metastatic renal cell Cancer (MRCC): A phase II study, preliminary results. Journal of Clinical Oncology 26(15_suppl): 16011-16011, 2016

A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802. Medical Oncology 29(2): 761-767, 2012

Curability of poor-risk metastatic sarcomatoid renal cell carcinoma with the combination of gemcitabine, 5-fluorouracil, and interferon-alfa: a case report of a 55-year-old man with a 10-year complete remission. Clinical Genitourinary Cancer 11(3): 370-373, 2014

Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma. Cancer 121(19): 3435-3443, 2016

Capecitabine in combination with interferon-alpha in interleukin-2-refractory metastatic renal cell carcinoma (MRCC). Journal of Clinical Oncology 26(15_suppl): 16088-16088, 2016

Phase 1/2 study of sunitinib in combination with gefitinib in patients (pts) with metastatic renal cell carcinoma (mRCC). 2007

Carcinoma of Unknown Primary Site (CUP) With Metastatic Renal-Cell Carcinoma (mRCC) Histologic and Immunohistochemical Characteristics (CUP-mRCC): Results From Consecutive Patients Treated With Targeted Therapy and Review of Literature. Clinical Genitourinary Cancer 2018, 2018

Sorafenib after combination therapy with gemcitabine plus doxorubicine in patients with sarcomatoid renal cell carcinoma: a prospective evaluation. European Journal of Medical Research 15: 287-291, 2012

Sorafenib as a second-line and sequential therapy for patients with metastatic renal cell carcinoma (mRCC): Analysis for safety and activity on sunitinib progressive pts. Journal of Clinical Oncology 26(15_suppl): 16100-16100, 2016